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ABSTRACT
Objectives Osteoarthritis (OA) structural status is 
imperfectly classified using radiographic assessment. 
Statistical shape modelling (SSM), a form of machine- 
learning, provides precise quantification of a 
characteristic 3D OA bone shape. We aimed to determine 
the benefits of this novel measure of OA status for 
assessing risks of clinically important outcomes.
Methods The study used 4796 individuals from the 
Osteoarthritis Initiative cohort. SSM- derived femur bone 
shape (B- score) was measured from all 9433 baseline 
knee MRIs. We examined the relationship between 
B- score, radiographic Kellgren- Lawrence grade (KLG) 
and current and future pain and function as well as total 
knee replacement (TKR) up to 8 years.
Results B- score repeatability supported 40 discrete 
grades. KLG and B- score were both associated with risk 
of current and future pain, functional limitation and TKR; 
logistic regression curves were similar. However, each 
KLG included a wide range of B- scores. For example, for 
KLG3, risk of pain was 34.4 (95% CI 31.7 to 37.0)%, 
but B- scores within KLG3 knees ranged from 0 to 6; 
for B- score 0, risk was 17.0 (16.1 to 17.9)% while for 
B- score 6, it was 52.1 (48.8 to 55.4)%. For TKR, KLG3 
risk was 15.3 (13.3 to 17.3)%; while B- score 0 had 
negligible risk, B- score 6 risk was 35.6 (31.8 to 39.6)%. 
Age, sex and body mass index had negligible effects on 
association between B- score and symptoms.
Conclusions B- score provides reader- independent 
quantification using a single time- point, providing 
unambiguous OA status with defined clinical risks across 
the whole range of disease including pre- radiographic 
OA. B- score heralds a step- change in OA stratification 
for interventions and improved personalised assessment, 
analogous to the T- score in osteoporosis.
INTRODUCTION
Osteoarthritis (OA) is a serious disease resulting in 
pain, loss of function and reduced quality of life 
and represents a major public health problem.1 
The pathophysiology of OA involves multiple 
tissues, with deterioration of both cartilage and 
bone considered integral to the OA process.2 End- 
stage disease can be successfully treated with joint 
replacement, but there has been limited progress 
with interventions that address earlier OA stages.
OA structural pathology has conventionally been 
assessed using X- rays. Radiographic determination 
of OA structural status is imprecise due to its depen-
dence on acquisition method and reader reliability.3 
The most common scoring system, the semiquan-
titative Kellgren- Lawrence grade (KLG, scored 
0–4), assesses cartilage and bone as well as (indi-
rectly) meniscal changes.4 Semiquantitative radio-
graphic assessment has driven our understanding of 
structure- symptom relationships,5 demonstrating 
associations at group, but not at individual patient 
level.
MRI has enabled detailed understanding of three- 
dimensional OA structural pathology and revealed 
multiple pathologies not evident on X- rays. MRI 
provides direct quantitative assessment of carti-
lage and bone6 7 and the most responsive imaging 
biomarkers. However, there remains a strong 
need for validated surrogate measures of clinically 
important outcomes, which provide OA status from 
a single time point, without longitudinal evaluation.
In areas such as hypertension and diabetes, the 
provision of a single, quantitative measurement has 
provided breakthroughs in clinical management 
and drug discovery. In the management of osteopo-
rosis, the dual- energy absorptiometry- based T- score 
Key messages
What is already known about this subject?
 ► There is a huge unmet need for accurate and 
reliable assessment of osteoarthritis (OA) status.
 ► MRI has demonstrated much more pathology 
but has been largely constrained to reader- 
dependent semiquantitative assessment.
 ► Machine- learning enables accurate, reader- 
independent quantification and we have 
previously demonstrated it can measure a 
characteristic OA three- dimensional bone shape 
with good precision.
What does this study add?
 ► Through application of machine learning, this 
study has provided a new highly reliable and 
precise measure of OA status, a quantified 3D 
femur bone shape termed the B- score.
How might this impact on clinical practice or 
future developments?
 ► B- score should enable improved stratification 
for interventions, accurate classification 
across the range of OA severity and improved 
personalised assessment, analogous to the role 
of the T- score in osteoporosis.
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replaced imprecise and insensitive measures based on radio-
graphic bone assessment and photon absorptiometry, creating a 
single standard measure.
In the field of clinical imaging, the appearance of a tissue can 
be learnt and then applied to automatically find and delineate 
that tissue in new, unseen images.8 Importantly, this approach is 
agnostic, being independent of prior expert opinion. Statistical 
shape modelling (SSM), a type of supervised machine- learning, 
employs principal component analysis to reduce complex 3D 
geometric shapes to a single metric value.9 Using SSM, we have 
identified a characteristic OA 3D bone shape, incorporating 
osteophyte ridge formation and widening and flattening of the 
articular surfaces. This bone shape predicts radiographic onset 
of OA,10 is associated with radiographic structural progres-
sion11 and discriminates knees with OA from non- OA.12 In each 
of these studies, the femur had the greatest discrimination and 
responsiveness, and we have focused this study on femur shape, 
here termed ‘B- score’. To determine the value of B- score as a 
measure of OA status, we examined its precision, relationship 
with the existing radiographic standard (KLG) and explored the 
relationships of both B- score and KLG with clinically important 
outcomes: pain, function and total knee replacement (TKR) 
surgery.
METHODS
Quantifying tissue shape
Patient image data
Data were obtained from the Osteoarthritis Initiative (OAI), a 
multicentre, longitudinal, prospective observational study of 
knee OA; bilateral knee MR images were collected in a stan-
dardised way together with clinical data from 4796 individuals 
with, or at risk of developing knee OA.13 Data are publicly avail-
able at https:// data- archive. nimh. nih. gov/ oai/.
High- resolution sagittal 3D dual- echo at steady- state water- 
excitation (DESS- we) knee MRI images were acquired on recruit-
ment into the OAI and at 1, 2 and 4 year timepoints, using a 3T 
MRI system (MAGNETOM Trio, Siemens Healthcare, Erlangen, 
Germany). Image acquisition parameters have been published in 
detail.14
Statistical shape modelling
Femur bones were automatically segmented from DESS- we 
images using active appearance models (AAMs), a type of SSM 
trained to search images, provided by Imorphics (Manchester, 
UK). AAMs are proven technology that can segment knee 
bone surfaces with submillimetre accuracy.12 15 AAMs were 
constructed using a training set, from DESS- we images, selected 
to provide examples of all stages of OA.16
We constructed an ‘OA vector’, defined as the line passing 
through the mean shape of a population with OA (OA Group, 
defined as all knees with KLG ≥2 at all four time points of 0, 1, 
2 and 4 years) and a population without OA (Non- OA Group, 
defined as those with KLG of 0 at each of the same time points).
B-score
Distances along the OA vector are termed ‘B- score’, with the 
origin (B- score 0) defined as the mean shape of the Non- OA 
Group for each gender. 1 unit is defined as 1 SD of the Non- OA 
Group along the OA vector (positive values towards the OA 
Group). Representative examples of differences in femur bone 
shape at various B- scores, and a heat map of the areas which 
change most with increasing B- score are shown in figure 1. The 
range of B- scores in the Non- OA Group was defined as the 95% 
confidence limits of B- scores in this group, being ±1.96; this 
enabled delineation of the Non- OA range of B- scores in figures 
and analysis. Expanded details of the methods for AAM search 
and construction of B- score are provided in online supplemental 
methods.
Measurement repeatability
All visually acceptable DESS- we images from the OAI retaken 
on the same day were assessed; a test- retest set (1 week apart) 
of those with definite OA were also analysed.12 16 Repeatability 
Figure 1 Figure shows change in shape for the anterior femur (top row) and posterior femur (bottom row), for various B- scores. Red indicates 
where there is an increase in size (locally calculated, based on anatomically corresponded triangles from the shape model), and blue indicates 
decrease in size (locally); scale shows percentage in area size change of each triangle. Change tends to be greatest around the edge of the cartilage 
plate (osteophyte region), but it also occurs in central subchondral regions where the bone flattens out.
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(smallest detectable difference, SDD) was calculated as the 95% 
limits of agreement between the two image measurements, using 
the Bland- Altman method.
KLG reading was performed in the OAI using carefully 
acquired radiographs, with the knee positioned using a custom- 
designed frame allowing for a standard knee flexion angle and 
reporting position of the X- ray source.17 Two expert readers 
independently assessed each radiograph; differences were adju-
dicated by a group including a more senior reader.
STATISTICAL ANALYSIS
All analyses were conducted using SAS V.9.4 (Cary, North Caro-
lina, USA). Values for the associations with clinical outcomes are 
presented as proportion of the relevant population; referred to 
throughout as risk of a clinical outcome.
Pain by B-score and KL grade
Pain was assessed using the 7- day pain severity numeric rating 
scale (NRS, 0–10). Current pain was defined as NRS score 
at baseline, future pain as the median value of all later time-
points (up to 8 years, average follow- up 5 years). Knees were 
categorised as moderate pain (score ≥4) and severe pain (score 
≥8).18 19 As a sensitivity analysis, we assessed WOMAC- A pain 
(0–20 scale, moderate ≥4 and severe ≥8). Logistic regression 
analyses were performed for current and future pain as defined 
above against either KLG or baseline B- score, with no additional 
covariates.
Function by B-score and KL grade
Function was assessed using WOMAC function score (0–68), for 
the knee with the highest B- score per person. Current function 
was defined at baseline, future function as the median value at 
all later timepoints (follow- up as for pain). Moderate functional 
limitation was defined as ≥20 and severe as ≥35.20 21 Logistic 
regression analyses were performed for current and future func-
tion as defined above against either KLG or baseline B- score, 
with no additional covariates.
Total knee replacement by B-score and KL grade
KL grade and B- score were independently assessed to determine 
predictors of TKR at any point during the follow- up period for 
an individual knee, defined as having an adjudicated TKR within 
a follow- up period of up to 8 years. This was assessed by model-
ling TKR as outcome against B- score and KLG separately using 
logistic regression models.
Logistic regression of KLG by B-score quartiles
To assess whether B- score provided additional information over 
KLG, two modelling approaches were considered. In the first, 
individual KLG groups were subdivided into quartiles based on 
B- score and assessed for the five clinical outcomes of current 
and future pain and function, and TKR, using logistic regres-
sion. The second approach involved initially modelling each 
outcome as described previously with KLG, then adding B- score 
to each model and assessing whether the regression coefficient 
for B- score was statistically significant and then calculating the 
resulting area under the curve (AUCs) for the combined models.
Confounders of B-score and risks of clinical outcomes
Potential confounders of the relationship between B- score 
and the risks of current pain, function and TKR were investi-
gated by adjusting the models for age, sex, ethnicity, body mass 
index (BMI), alignment, previous knee surgery, non- steroidal 
anti- inflammatory drugs (NSAIDs) use and smoking status. A 
description of these variables is shown in the online supple-
mental methods section.
RESULTS
Participant characteristics
Table 1 provides demographic and baseline characteristics. More 
than 96% of OAI participants had both knees assessed (total 
knees n=9433). Age ranged from 45 to 79 years. Median BMI 
was 28 kg/m2 (range, 16.9–48.7).
Repeatability
A total of 139 knees were imaged twice on the same day within 
the OAI: the repeatability (SDD) of B- score in this group was 
0.251 (B- score units). This group was representative of the 
whole OAI dataset (86 female, KLG 0, 1, 2, 3, 4 as fraction: 
33%, 20%, 31%, 12%, 4%, BMI mean (SD) 30.3 (5.23); mean 
age (SD) 62.7 (9.45). A total of 35 knees were imaged in the test- 
retest set, at baseline and 1 week: SDD of B- score in these images 
was 0.254. This represents 2.5% of the likely range of B- scores 
(−3 to +7 in this study).
Relationship of B-score with KL grade
Distribution of B- score by KLG is shown in figure 2. There was 
a large range of B scores for each KLG, reflecting the increased 
measurement sensitivity of the measure, with B- score range 
increasing with KLG. Mean B- score had a non- linear associa-
tion with KLG, increasing more rapidly at grades 3 and 4; CIs 
were wider with increased KLG. For example, the 95% confi-
dence limits of B- score for a KLG3 knee (n=1237) were –0.2 
and +6.0. 3.4% of KLG0 knees had B- scores greater than the 
non- OA range, KLG1:7.9%, KLG2:33.1% KLG3:57.6%, 
Table 1 Demographic and baseline characteristics
Parameter
Males
N=1992
Females
N=2799
Combined
N=4791
Knee MRIs in the OAI dataset 
at baseline
n=1992 n=2799 n=4791
Both right and left 1929 (97) 2713 (97) 4642 (97)
Right only 37 (2) 49 (2) 86 (2)
Left only 26 (1) 37 (1) 63 (1)
Age (y) n=1992 n=2799 n=4791
Mean (SD) 60.9 (9.5) 61.3 (9.0) 61.2 (9.2)
Median percentile (25th, 75th) 59 (53 to 70) 61 (54 to 69) 61 (53 to 69)
Min, Max 45 to 79 45 to 79 45 to 79
Race n=1989 n=2797 n=4786
White 1666 (84) 2122 (76) 3788 (79)
Black or African American 276 (14) 595 (21) 871 (18)
Asian 13 (1) 32 (1) 45 (1)
Other non- white 34 (1) 48 (2) 82 (2)
Current cigarette smoker n=1964 n=2766 n=4730
No 987 (50) 1513 (55) 2500 (53)
Yes 977 (50) 1253 (45) 2230 (47)
Use of NSAIDs at Baseline n=1983 n=2796 n=4779
Yes 463 (23) 720 (26) 1183 (25)
No 1520 (77) 2076 (74) 3596 (75)
BMI (m/kg2) n=1990 n=2797 n=4787
Mean (SD) 28.8 (4.15) 28.5 (5.27) 28.6 (4.84)
Median percentile (25th, 75th) 28.5 (25.7 to 31.5) 28.1 (24.4 to 32.0) 28.2 (25.1 to 31.7)
Min, Max 18.3 to 44.6 16.9 to 48.7 16.9 to 48.7
All values are n (%) unless stated.
*BMI denotes body mass index, MRI magnetic resonance imaging, NSAIDS nonsteroidal anti- 
inflammatory drugs, and OAI Osteoarthritis Initiative.
 on N
ovem
ber 25, 2020 by guest. P
rotected by copyright.
http://ard.bm
j.com
/
A
nn R
heum
 D
is: first published as 10.1136/annrheum
dis-2020-217160 on 13 N
ovem
ber 2020. D
ow
nloaded from
 
4 Bowes MA, et al. Ann Rheum Dis 2020;0:1–7. doi:10.1136/annrheumdis-2020-217160
Osteoarthritis
KLG4:89.3%. Proportions of B- score bins classified by KLG are 
shown in online supplemental table S4 and online supplemental 
figure S3.
KLG and clinically important outcomes
The risk of moderate knee pain or limitation of function increased 
across the range of KLG from around 10% to around 60%; this 
was not linear, and risk increased more rapidly between KLG 3 
and 4 (figure 3). Risks of severe knee pain or severe limitation 
of function also increased from 2% to 15% and 8% to 35%, 
respectively. Risk of TKR increased in a curvilinear manner, with 
risk increasing approximately 2.5- fold for each increase in KLG. 
Risk of future pain and function are shown in online supple-
mental figure S1.
B-score and clinically important outcomes
The risks of moderate knee pain or loss of function increased 
across the range of B- score from around 10% to around 60% 
and are curvilinear (figure 4 and online supplemental table S1). 
Risks of severe knee pain or severe function limitation increased 
similarly. Risk of TKR also increased similarly. Risks of future 
pain and function are shown in online supplemental figure S1. 
The distribution of pain, function and other OA- related factors 
at baseline is shown in online supplemental table S2. AUCs for 
the relationship of B- score and all five outcomes were compa-
rable with those found for KLG and those outcomes (online 
supplemental table S3).
Additional information provided by B-score
Within KLG2-4, ORs for all clinical outcomes varied signifi-
cantly between lowest and highest B- score quartiles (p<0.001) 
(for KLG3 knees, see table 2). No statistically significant differ-
ences were found between lowest and highest quartiles in KLG 
0 and 1 knees. In terms of discrimination, addition of B- score 
resulted in improvement in the AUCs in all models, although 
of small magnitudes (online supplemental table S3), while the 
regression coefficient for B- score was statistically significant 
(p<0.05) in all models.
Figure 2 Distribution of B scores by KL grade are displayed for males 
and females (mean and 95% CIs for each grade). Mean B score for each 
KL grade is noted above each line.
Figure 3 Error bars show 95% confidence limits for each measure. Pain: moderate or greater pain was defined as NRS pain ≥4 on the 10- unit scale 
(black points); severe pain as NRS pain ≥8 (grey points). Function: moderate or greater limitation of function was defined as function ≥20 on the 
68- point WOMAC function scale (black points); severe loss of function was defined as ≥36 (grey points). TKR—risk of total knee replacement over 
follow- up period (up to 8 years, average follow up 5 years).
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Increased discrimination of all risks, using B-score at 
individual patient level
The increased utility of B- score is demonstrated by considering 
a KLG3 knee. The mean(CI) risk of a moderately painful knee 
based on this KLG was 34.4 (31.7 to 37.0)%. B- score within 
KLG3 knees ranged (95% CI) from 0 to 6; if the knee had a 
B- score of 0 the risk of a moderately painful knee was 17.0 (16.1 
to 17.9)% while for a B- score of 6 it was 52.1 (48.8 to 55.4)%. 
The risk of a moderate limitation of function for a KLG3 was 
20.6 (18.2 to 22.9)% if the knee had a B- score of 0 the risk of 
moderate function limitation was 11.4 (10.4 to 12.5)% while 
for a B- score of 6 it was 40.6 (36.6 to 44.6)%. For TKR, KLG3 
knee had risks of 15.3 (13.3 to 17.3)%, whereas B- score 0 had 
negligible risk of TKR 2.3 (2.0 to 2.6)% and B- score six had a 
risk of 35.6 (31.8 to 39.6)%.
Confounders of, and additional information provided by, 
B-score
After adjustment for covariates the effect sizes from regression 
were still classified as ‘small’ for the risk of pain, function or 
TKR (online supplemental table S1).
DISCUSSION
Machine- learning has made possible the development of a quan-
titative measure of OA status; we have termed this the B- score. 
In this large observational cohort, B- score produced logistic 
regression models for clinically important outcomes, which were 
very similar in terms of predictive validity to those of the existing 
radiographic standard, providing construct validity for this new 
measure. However, by providing a scalar measure enabling 
Table 2 ORs and 95% CIs for B score quartiles among KLG 3 & 4 knees, compared with the lowest B score quartile, for all current and future 
clinical outcomes
Outcome B- Score Quartile 2 B- ScoreQuartile 3 B- scoreQuartile 4
Pain moderate - current 1.36 (0.95,1.94) 1.76 (1.24,2.49)*** 2.4 (1.69,3.4)***
Pain severe - current 1.43 (0.67,3.05) 3.13 (1.59,6.16)** 3.54 (1.8,6.93)***
Function loss moderate - current 1.67 (1.12,2.51)* 1.91 (1.28,2.86)** 2.35 (1.58,3.49)***
Function loss severe - current 1.22 (0.5,2.99) 2.66 (1.21,5.84)* 2.03 (0.89,4.63)
Pain moderate - future 1.95 (1.33,2.86)*** 2.54 (1.74,3.69)*** 3.18 (2.18,4.62)***
Pain severe - future 1.25 (0.49,3.21) 3.28 (1.46,7.4)** 3.62 (1.61,8.14)**
Function loss moderate - future 1.61 (0.99,2.62) 2.83 (1.79,4.48)*** 3.52 (2.23,5.55)***
Function loss severe - future 1.23 (0.37,4.06) 2.95 (1.05,8.29)* 2.16 (0.73,6.41)
Total knee replacement 1.21 (0.73,2.01) 1.51 (0.93,2.47) 2.58 (1.62,4.09)***
*P<0.05, **p<0.01, ***p<0.001.
Figure 4 Error bars show 95% CIs for each measure. Moderate or greater pain was defined as NRS pain ≥4 on the 10- unit scale (black lines); severe 
pain as NRS pain ≥8 (grey lines). Moderate or greater limitation of function was defined as function ≥20 on the 68- point WOMAC function scale 
(black lines); severe limitation of function was defined as ≥36 (grey lines). TKR—risk of total knee replacement over follow- up period (up to 8 years, 
average follow- up 5 years). Limits of non- OA group B- scores are provided using a dotted line and greyed area.
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at least 40 measurable subdivisions for OA structural change, 
B- score provides increased discrimination of risk over KLG for 
all clinically important outcomes. As a fully automated (reader- 
independent) measurement, B- score allows for rapid analysis of 
large datasets; and in both clinical trials and routine practice, 
provides a consistent measurement metric. As a scalar measure 
(compared with the categorical KLG), B- score permits the use of 
more powerful statistical methods for analysis.
The primary utility afforded by the precision of B- score is 
demonstrated by comparison with KLG. We have presented an 
example for KLG3 in the Results section, demonstrating the 
benefits conferred by having a range of B- scores within a single 
KLG. This applies for all KLG, even for a KLG0 knee, (often 
considered to be normal), for which the mean risk of moderate 
pain was 12%, while B- score risk range (−2 to +2) was 
10%–27%. In day- to- day clinical use, it is unlikely that KLGs 
can be as consistent and repeatable as those in the OAI, where 
images are carefully acquired and read. Several studies estimated 
inter- reader agreement of KLG and found a ‘moderate’ intraclass 
coefficient of around 0.5–0.7.22–24 In practice, this means that a 
KLG3 knee has an equal chance of being scored as KLG2, 3 or 
4. This misclassification profoundly affects the risks exemplified 
above: a KLG3 knee had a risk of between 13.3% and 17.3% 
of TKR within 8 years. If the knee is equally likely to be scored 
as KLG2 or KLG4, then this becomes 4.5%–45.5%, a 10- fold 
increase in CI.
B- score provides a measure of OA status across the whole 
range of OA structural severity, including early disease. This is 
often conceptualised as KLG2, but the findings of the current 
study show that 31% of those categorised as KLG2 had a 
B- score within the non- OA range, and KLG0-1 knees included 
8% with B- scores above the non- OA range. There is currently 
no consensus on a definition of ‘early’ OA, and B- score can 
provide a valuable measure. We have used the 95% CI of those 
who almost certainly do not have radiographic OA (B- score 
of ≤ 1.96), and this seems a well- validated basis for a cut- off 
point. In clinical trials, B- score would provide a reliable strat-
ification tool and has already shown to be a sensitive outcome 
measure.25 A number of therapies, including platelet- rich plasma 
and hyaluronic acid, are used in early OA,26 and their effect on 
OA structural progression can now be meaningfully assessed. 
Implications for clinical practice require further consideration, 
and at present may improve assessment of prognosis more than 
selection of therapy (given our limited non- surgical therapeutic 
options). However, B- score may initially provide clinical useful-
ness in situations where MRI is already commonly performed 
(eg, sporting injuries or ‘possible early OA’).
It was not the intention of this study to suggest that bone 
shape pathology is causally related with the clinically important 
outcomes; bone shape is likely reflecting a broader OA construct. 
It is widely believed that the clinically important outcomes used 
in this study are related to age, sex, ethnicity, BMI and align-
ment, and these covariates are often used as inclusion criteria 
in OA clinical trials. In this study, these covariates had negli-
gible effects on the ORs of the relationship between B- score, a 
measure of bone pathology, and clinically important outcomes.
We did perform a number of sensitivity analyses on the choice 
of symptom cut- points, in the absence of widespread consensus 
on what constitutes moderate and severe symptoms. As well as 
using a second tool, (WOMAC pain, see online supplemental 
figure S2) which showed a similar symptom- structure relation-
ship to the NRS score used in the main paper, we also performed 
sensitivity testing using values of 7, 8 or 9 as cut- off for ‘severe’ 
pain, and 32, 34 or 36 as cut- off points for function loss and 
found that the choice of any of these cut- off points was not an 
important effect (data not shown).
The strength of this work includes very large patient numbers, 
but there are limitations. We have not attempted to explore 
longitudinal change or relationship to cartilage as we focused 
on the benefits of this new measure at a single time point, and 
its clear relationships with clinically important outcomes. Our 
non- OA group, used to set the scale of B- score, was drawn from 
the OAI with a population aged 45–80, in contrast to the oste-
oporosis T- score which uses a reference population of healthy 
young adults. Although we used the DESS- we MR images in 
this study and have previously demonstrated that the method is 
applicable to similar MRI sequences,27 the method would need 
validation for other MRI sequences. We used a regression anal-
ysis for the risk of TKR, rather than hazard or incident rate 
analysis, as TKR was a ‘rare’ outcome in our data set, and also 
to allow the reader to compare estimates in our study (figures 3 
and 4). The machine- learning technology can almost certainly 
be applied to cheaper imaging methods such as CT. Although the 
method for B- score determination used in this study is propri-
etary, several methods for bone shape measurement have been 
published, and the measurement of bone shape is actively being 
pursued by multiple groups. The bone shape vector revealed 
here may not hold for very late stages of the disease, where 
fewer patient numbers were available in this study. When osteo-
phytes begin to carry load directly, they are likely to remodel 
and may produce shape changes that are less systematic than 
those reported here.
In conclusion, machine learning has enabled the development 
of a new objective, precise single time- point measure, B- score, 
representing OA status. B- score demonstrated similar relation-
ships to clinically important outcomes as the current radio-
graphic standard, but with the increased precision of B- score 
(providing approximately 10 times more detail on OA struc-
tural status), enabling better risk discrimination for clinically 
important outcomes. B- score should enable improved stratifica-
tion for interventions and improved personalised assessment, in 
the same way that bone mineral density and more specifically, 
the T- score, has done historically for osteoporosis.
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Supplementary Material: Machine-learning, MRI bone shape and important 
clinical outcomes in osteoarthritis: data from the Osteoarthritis Initiative 
SUPPLEMENTARY RESULTS 
Supplementary Table S1. Effect of correcting for covariates (Age, Sex, Race, 
BMI, Alignment, Previous Knee Surgery, Use of NSAIDS, Smoking Status) on 
risks of clinically important outcomes   
Outcome Variable 
Unadjusted 
Odds Ratio B-score 
[95% CI] (p-value)  
Adjusted 
Odds Ratio B-score 
[95% CI] (p-value)  
Current NRS Pain 
Moderate Pain 
1.322 [1.288,1.358] 
 (<0.0001) 
1.153 [1.084,1.227] 
 (<0.0001) 
Severe Pain 
1.314 [1.260,1.370] 
(<0.0001) 
1.184 [1.079,1.300] 
(0.0004) 
Current WOMAC Pain 
Moderate Pain 
1.322 [1.289,1.357] 
 (<0.0001) 
1.204 [1.131,1.281] 
(<0.0001) 
Severe Pain 
1.345 [1.300,1.391] 
(<0.0001) 
1.146 [1.060.1.239] 
(0.0006) 
Current Function (worst knee) 
Moderate limitation of function 
1.334 [1.300,1.368] 
(<0.0001) 
1.108 [1.033,1.188] 
(0.0039) 
Severe limitation of function 
1.333 [1.295,1.373] 
(<0.0001)
1.257 [1.100,1.436] 
(0.0008) 
Total Knee Replacement 
1.694 [1.624,1.767] 
(<0.0001) 
1.653 [1.508,1.811] 
(<0.0001)  
Potential confounders of the relationship between B-score and the risks of current pain, function and 
TKR were investigated by adjusting the models for age, sex, ethnicity BMI, alignment, previous knee 
surgery, NSAID use and smoking status. A description of these variables is shown in the 
Supplementary Methods section below. 
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Supplementary Table S2. Osteoarthritis Indicators at Baseline 
Parameter Males 
n = 3921 knees 
Females 
n = 5512 knees 
Combined 
n = 9433 knees 
WOMAC-A (pain) at baseline, n (%) n=3921 n=5512 n=9433 
0 to <4: No pain to low pain 2983 (76.1) 3942 (71.5) 6925 (73.4) 
4 to <8: Moderate pain 644 (16.4) 956 (17.3) 1600 (17.0) 
8 or more: Severe pain 294 (7.5) 614 (11.1) 908 (9.6) 
NRS (pain) at baseline, n (%) 
0 to <4: No pain to low pain 3146 (80.2) 4188 (76.0) 7334 (77.8) 
4 to <8: Moderate pain 600 (15.3) 975 (17.7) 1575 (16.7) 
8 or more: Severe pain 175 (4.5) 349 (6.3) 524 (5.55) 
Function limitation, n (%) n=3921 n=5512 n=9233 
0 to <20: No or low limitation 3480 (88.9) 4547 (82.5) 8027 (85.1) 
20 to <36: Moderate limitation 356 (9.1) 735 (13.3) 1091 (11.6) 
36 or more: Severe limitation 85 (2.2) 230 (4.2) 315 (3.3) 
n=3861 n=5393 n=9254 
0.81 (2.98) -1.07 (2.76) -0.28 (3.00)
0.50 (-1, 3) -1 (-3, 0) -1 (-2, 1.5)
Alignment (degrees)
Mean (SD) 
Median percentile (25th, 75th) 
Min, Max -11,15 -20, 11 -20, 15
Previous knee surgery, n (%) n=3921 n=5512 n=9433 
Yes 693 (17.7) 447 (8.1) 1140 (12.1) 
Kellgren-Lawrence Grade 
at baseline, n (%) 
n=3705 n=5129 n=8834 
0 1496 (40.0) 1927 (37.6) 3423 (38.8) 
1 653 (17.6) 924 (18.0) 1577 (17.9) 
2 824 (22.2) 1506 (29.4) 2330 (26.4) 
3 560 (15.1) 656 (12.8) 1216 (13.8) 
4 172 (4.6) 116 (2.3) 288 (3.3) 
B-score at baseline n=3921 n=5512 n=9433 
Mean (SD) 0.90 (1.77) 1.05 (1.78) 0.99 (1.78) 
Median percentile (25th, 75th) 0.61 (–0.23, 1.68) 0.77 (–0.18, 1.93) 0.71 (–0.20, 1.84) 
Min, Max –3.41, 8.69 –3.46, 9.97 –3.46, 9.97
WOMAC denotes Western Ontario and McMaster Universities Osteoarthritis Index.
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Supplementary Table S3. Area under the curve for logistic regression models of 
B-score and KL grade vs current clinical outcomes. 
Outc ome KL g rade 
B-score and
KL grade
B score 
64.88% 66.41% 63.73% 
65.45% 68.14% 65.28% 
66.1% 69.17% 65.0% 
67.26% 69.94% 67.67% 
Moderate Pain 
Severe Pain 
Moderate Functional Limitation 
Severe Functional Limitation 
   Total Knee Replacement 82.84% 85.02% 79.5% 
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Supplementary Table S4.  Proportions of KL grades by B-score, and B-score by 
KL grade 
KL Grade 
B-score range n 0 1 2 3 4 
< -3 to -2·5 33 79% 15% 6% 0% 0% 
< -2·5 to -2 112 77% 17% 4% 2% 0% 
< -2 to -1·5 221 73% 14% 12% 1% 0% 
< -1·5 to -1 449 63% 20% 14% 3% 0% 
< -1 to -0·5 768 60% 22% 15% 3% 0% 
< -0·5 to 0 1,098 58% 19% 19% 4% 0% 
> 0 to 0·5 1,258 50% 23% 21% 6% 0% 
> 0·5 to 1 1,230 44% 23% 25% 7% 1% 
> 1 to 1·5 994 34% 23% 30% 12% 1% 
> 1·5 to 2 729 23% 18% 37% 20% 2% 
> 2 to 2·5 514 14% 13% 45% 26% 2% 
> 2·5 to 3 371 9% 12% 40% 33% 6% 
> 3 to 3·5 267 4% 4% 39% 38% 15% 
> 3·5 to 4 202 0% 0% 50% 42% 8% 
> 4 to 4·5 169 1% 1% 41% 40% 18% 
> 4·5 to 5 148 0% 1% 36% 41% 22% 
> 5 to 5·5 105 0% 0% 26% 47% 27% 
> 5·5 to 6 71 0% 0% 38% 35% 27% 
> 6 to 6·5 53 0% 0% 15% 43% 42% 
> 6·5 to 7 34 0% 0% 15% 56% 29% 
Proportions of knees recorded as KL grades 0, 1,2,3,4 for 20 bins of B-score.  Note that measurement 
repeatability supports the use of 40 categories; we have used 20 here to ensure that outer bins 
contain sufficient numbers.  Data are graphically represented in Supplementary Figure S3.
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Supplementary Figure S1.  Future (A) NRS pain and (B) functional limitation by B-score 
Error bars show 95% confidence intervals for each measure. Moderate or greater pain was defined as 
NRS pain ≥4 on the 10-unit scale (black lines); severe pain as NRS pain ≥8 (grey lines). Moderate or 
greater limitation of function was defined as function ≥10 on the 68-point WOMAC function scale 
(black lines); severe loss of function was defined as ≥20 (grey lines). Limits of Non-OA group B-
scores are provided using a dotted line and greyed area. Future values were determined as the 
median value at all follow-up time points (excluding baseline, up to 8 years, average follow-up 5 
years). 
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Supplementary Figure S2. Current (A) and future (B) WOMAC pain by B-score 
Error bars show 95% confidence intervals for each measure. Moderate or greater pain was defined as 
WOMAC pain ≥4 on the 10-unit scale (black points); severe pain as WOMAC pain ≥8 (grey points). 
Limits of Non-OA group B-scores are provided using a dotted line and greyed area. 
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 Supplementary Figure S3. Distribution of B-scores by KL Grade 
Graphic representation of data in Supplementary Table S4
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SUPPLEMENTARY METHODS 
Definition of variables and assessment of confounders 
All data from the Osteoarthritis Initiative (OAI) that were utilised in this study are publicly 
available at https://data-archive.nimh.nih.gov/oai.   
For the different outcomes assessed, the influence of covariates (both confounders and 
competing exposures) chosen a priori from previously established clinical relationships was 
evaluated. Given the large sample size, both the statistical significance and the size of the 
estimates were considered. The covariates considered and adjusted for in the regression 
models were age, sex, BMI, ethnicity, previous knee surgery, alignment, NSAID use and 
smoking status described in more detail below.  
Covariates were coded as recorded by the OAI. Age was modelled as a continuous variable 
in years, sex was binary (male or female), BMI as a continuous variable in kg/m2. Ethnicity 
was categorised as White or Caucasian, Black or African-American, Asian, Other Non-white. 
Previous knee surgery was modelled as a binary variable coded as zero if participant had no 
history of previous surgery and one if they reported any previous knee surgery. In the OAI 
previous knee surgery was defined as “history of knee surgery (including arthroscopy, 
ligament repair, and meniscectomy)”. Alignment was measured using a goniometer and 
recorded in degrees which was modelled as a continuous variable in degrees. NSAID use 
was modelled as a binary variable (yes or no). The definition of NSAID use was any use of 
prescription or non-prescription NSAIDS (e.g., Ibuprofen, Diclofenac, Aspirin…) for joint pain 
or arthritis for more than half the days of the month in the past 30 days. Smoking status was 
modelled as a categorical variable with 3 levels (never, current and former). 
The variables considered for the regression models were based on a priori relationships 
between the outcomes. For TKR for example, we considered clinically important risk factors 
such as age, gender, weight, and pain, which may influence the surgeon`s decision to 
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operate. We also considered whether health insurance could affect the outcome with 
participants potentially not offered a TKR for financial reasons; however, on exploration of 
the data we found that 98% of participants that had a TKR had some form of health 
insurance while 96% of those not having a TKR had insurance. 
Tests for interactions 
Interactions, including that for age were considered during an initial analysis, but as the 
differences between univariable and adjusted models showed that the odds ratios 
represented small effects after adjustment, a parsimonious model was chosen as the final 
model, excluding interactions. 
Statistical Shape Modelling 
Femur bones were automatically segmented from DESS-we images using active 
appearance models (AAMs), a type of SSM trained to search images, provided by Imorphics 
(Manchester, UK). AAMs are proven technology, which can segment knee bone surfaces 
with sub-millimetre accuracy [1, 2] [references 15, 16 respectively in main paper]. AAMs 
were constructed using a training set, consisting of expert manual segmentations of DESS-
we images, selected to provide examples of all stages of OA. The training set was selected 
to contain examples of each stage of OA (43 KLG0 and KLG1, 7 KLG2, 28 KLG3, 18 KLG 4) 
[3] [reference 17 in main paper]. Accuracy of bone segmentation was excellent, with point-to-
surface accuracy against careful manual segmentation of ± 0.49mm (95% confidence limits 
of error), and repeatability of all bone measurements was excellent with typical coefficient of 
variations of 0.4% to 0.6% [1]. Adding additional training examples to the model beyond the 
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96 examples, with differing degrees of osteoarthritis, did not increase segmentation 
accuracy. 
The construction of an AAM parameterises femur bone shape using principal component 
analysis. Each time that a femur bone shape is identified within an image using an AAM, the 
femur bone shape is returned as a set of principal components. 
OA Vector 
Using the principal components from the AAM, we calculated the mean shape from two 
populations: 
1. The “Non-OA group”, being the group of all knees with KLG0 radiograph reading at
0,1,2 and 4 years in the OAI (n=885), regardless of sex
2. The “OA group”, being the group of all knees with KLG ≥2 at 0, 1, 2 and 4 years (n =
1,713), regardless of sex.
There is no risk of over-training any subsequent models using 2,597 knees, as the only 
information taken from these populations of knees was the mean shape of the two groups. 
An “OA vector” was defined as the line passing through the mean shape of the Non-OA 
group shape, and the OA group (Supplementary Figure S4). 
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Supplementary Figure S4. Sammon plot illustrating the shape distributions of 
600 femurs used in the training set and the OA vector.
Figure shows the population of the training set, randomly sampled down to 600 points for legibility of 
figure. A Sammon plot reduces all of the principal component dimensions into 2 dimensions while 
preserving the distances between shapes as far as possible. Green circle shows the average shape 
of the Non-OA group (dark grey circles), and red circle the average shape of the OA group (light grey 
circles). Dotted green line is the OA vector, the line which passes through these two mean shapes. 
Histograms showing the projection of points from the Non-OA and OA groups onto the OA vector is 
shown in Supplementary Figure S5 below.  
B-Score and sex
Each parameterized femur bone shape was projected orthogonally onto the OA vector to 
provide a distance along the OA vector. This distance was then normalised as follows: the 
origin (B-score of 0) was defined as the mean shape of the Non-OA Group for each sex. 
Means were determined separately for males and females (although the OA vector is 
constructed using both sexes). Males and females (with or without OA) have systematically 
different 3D bone shape [4] [reference not cited in main text], other than the OA shape 
11 
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described here, resulting in a systematic difference along the OA vector for each sex. This is 
corrected, by calculating the means separately for each sex, but continuing to use the OA 
vector which contains both sexes. The distribution of male and female knees from the Non-
OA or OA groups, after the correction are shown in Supplementary Figure S5. 
Preparing entirely separate models for sex did not improve classification of OA vs Non-OA, 
sensitivity to change, and the logistic regression models for pain, function and TKA were 
indistinguishable from those using a vector containing all males and females (data not 
shown). As a result, a single vector combining the sexes was used for this study, with the 
origin corrected separately for males and females. Scale is defined as 1 standard deviation 
of the distribution of the Non-OA Group along the OA vector (with positive direction being 
toward the OA Group).  
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Supplementary Figure S5: Distribution of Non-OA and OA groups following 
correction of means.  
A normal distribution of mean value 0 and a standard deviation of 1 is shown in each histogram using 
dotted line.  Both males and females from the Non-OA group (confirmed KLG0 over 4-year period), 
are normally distributed along the OA vector, centered on 0 after correction for sex. 
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